Jubayer Hossain

Position

Associate professor

Affiliation

Research groups

Short info

My research focuses on translational oncology and biopharmaceutical development, with a focus on advanced therapeutic modalities for malignant tumors. I engineer and evaluate lentiviral vector-based gene therapies in various in vitro and in vivo models. My work also spans targeted gene delivery, ant
Research

My research focuses on translational oncology and biopharmaceutical development, with a focus on advanced therapeutic modalities for malignant tumors. I engineer and evaluate lentiviral vector-based gene therapies in various in vitro and in vivo models. My work also spans targeted gene delivery, anti-cancer immunotherapy, investigation of cell death mechanism and intracellular trafficking relevant to biopharmaceutical optimization. Affiliated with the Department of Pharmacy at Nord University and the Institute of Biomedicine at the University of Bergen, I conduct internationally collaborative, preclinical research aimed at advancing novel gene medicines toward clinical translation.

Teaching

Teaching:

Supervision:

  • PhD-candidates: 3
  • MSc students: 8
  • Medicine students: 2
  • BSc students: 2
Publications

2026

1. Andersen JK,........Hossain JA*. Tropism Profiling of Lentiviral Three Vector Pseudotypes in Diverse Brain Tumor Models. Pharmaceutics . 2026 Jan 22;18(1):137. IF: 5,5

2025

  1. Wenjing Zhou, .......Hossain JA, ...Bjerkvig R. Development of a highly differentiated rat brain organoid model for exploring glioblastoma invasion dynamics and therapy. Neuro Oncol . 2025 Nov 24:noaf271.IF: 16,4
  2. Solel E, ...... Hossain J, Miletic H. Gasdermin E in glioblastoma -pyroptosis resistance and tumor-promoting functions. Cell Death Discov. 2025 Jun 21;11(1):284. IF: 7

2023

  1. Sajib SS, Hossain JA and Das MK. Stem Cell-Based Regenerative Medicine Therapy in Cancer. In: Haider, K.H. (eds) Handbook of Stem Cell Applications. Springer, Aug, 2023 IF: Ikke aktuelt
  2. Watson D, ...... Hossain JA...Lathia J. GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. Nature Cancer, May, 2023, IF: 28.5

2022

  1. Ferreira T, ..... Hossain JA, ......and Marchini A. Oncolytic H-1 Parvovirus Hijacks

    Galectin-1 to Enter Cancer Cells. Viruses . 2022 May 11;14(5):1018, IF 5.8

  2. Andersen JK, Miletic H, Hossain JA*. Tumor-associated macrophages in gliomas – basic

    insights and treatment opportunities. Cancers (Basel) . 2022 Mar 4;14(5):1319., IF 6.6

  3. Joseph JJ, Magaut CR, ..... Hossain JA, ...., Daubon T, Miletic H. TGF-β promotes

    microtube formation in glioblastoma through Thrombospondin. Neuro Oncol . 2022 Apr 1;24(4):541-55. IF: 15.9

Publikasjonsliste Jubayer A. Hossain, PhD

2021

9. Zhao D, Zhang H, ..... Hossain JA, ... Glass R 1and Kälin R. Comparing Tumor Cell Invasion and Myeloid Cell Composition in Compatible Primary and Relapsing Glioblastoma. Cancers 2021, 13. 2021. IF: 6.6

10. Kulkarni A, Ferreira T, ......., Hossain JA, ......Brino L and Marchini A. Oncolytic H1- parvovirus hijacks laminins for cell attachment and entry. Nat Commun. 2021 Jun 22;12(1). IF: 15,7

11. The Potentials and Pitfalls of Using Adult Stem Cells in Cancer Treatment. Das MK, Miletic H, and Hossain JA*. Advances in Experimental Medicine and Biology. 2021. IF: 2.4.

2020

  1. Hossain JAÑ, Miletic H. Letter regarding “Extensive brainstem infiltration, not mass effect,

    is a common feature of end-stage cerebral glioblastomas”. Neuro-Oncology. 2020. IF: 15.9

  2. Hossain JAÑ*, Marchini A, Fehse B, Bjerkvig R and Miletic H. Suicide Gene Therapy for the treatment of High-grade Gliomas: Past Lessons, Present Trend and Future Remarks. Neuro-

    Oncology Advances, 2 (1) 2020.. IF: 4,1

2019

  1. Hossain JAÑ, Ystaas LAR, Latif MA, Ninzima S, Joseph JV, Talasila KM, Ghimire J,

    Riecken K, Fehse B, Bjerkvig R and Miletic H. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma, Neuro-Oncology, 21(7). 2019. IF: 16,4

  2. Hossain JAÑ, Riecken K, Miletic H, Fehse B. Cancer Suicide Gene Therapy with TK.007. Methods Mol Biol. 2019; 1895:11-26. IF: ikke aktuelt.

    <2019

  3. Talasila KM, Røsland GV, Hagland HR, .... Joseph JV, Hossain JA, Vallar L, ....... Bjerkvig

    R and Miletic H. The angiogenic switch leads to a metabolic shift in human glioblastoma.

    Neuro Oncol. 2017 Mar 1;19(3):383-393. IF: 15.9

  4. Eskilsson E, Rosland GV, ......Välk K, Al Hossain J, ....Bjerkvig R, and Miletic H. EGFRvIII

    mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro Oncol. 2016 Dec;18(12):1644-1655. Epub 2016 Jun 10. IF: 16,4

  5. Hossain JAÑ, Ystaas LR, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J,Miletic H. Lentiviral HSV-Tk.007 mediated suicide gene therapy is not toxic for normal brain cells. J Gene Med. 18(9).2016. IF: 2,2
  6. Samoylenko AY, Hossain JAYÑ, Mennerich D, Kellokumpu S, Hiltunen JK, Kietzmann T. Nutritional Countermeasures Targeting Reactive Oxygen Species in Cancer: From Mechanisms to Biomarkers and Clinical Evidence. Antioxid Redox Signal. 2013 Dec 10; 19(17): 2157–2196. YCo-first author. IF: 7,0
Projects
  • Anti-cancer Therapy
  • Immunotherapy of solid cancers
  • Suicide Gene Therapy for the Treatment of Brain tumors
  • Oncolytic Virotherapy by H1 PV Virus for the Treatment of Various Cancers
  • Molecular Mechanism of Bystander effect in HSV-TK/GCV Gene therapy